The sentence I hear several times a week
A patient sits down in my clinic, points to the shadows beneath her eyes, and says it: "Doctor, I want filler here."
Perhaps a third of the time, filler is the right answer. Perhaps a third of the time, filler would help a little but would not address what is actually causing the problem. And in the remaining cases, injecting filler into that hollow would make her look worse, and it would keep making her look worse for years.
The under-eye region is the most technically demanding area in facial aesthetics. It is also, unfortunately, one of the most casually treated. This article explains what is really happening beneath your eyes, why the diagnosis matters far more than the product, and how we approach it at AOKLINIK.
First, the anatomy nobody explains
The hollow you see is not simply "missing volume".
Running from the inner corner of your eye diagonally down and outward is the tear trough ligament, a true osteocutaneous ligament anchoring skin directly to the maxillary bone. Laterally, it continues as the orbicularis retaining ligament. Together they form a fixed tether where the thin, mobile eyelid tissue is bound down to the skeleton.
Above that line, the skin is roughly half a millimetre thick, the thinnest anywhere on the human body, with almost no subcutaneous fat to cushion it. Below it, the cheek skin is several times thicker.
This creates the shadow. Light falls across a fixed groove between two tissue planes of completely different thickness. It is architectural, not simply a deficiency of volume, and it explains why filling the hollow without respecting the ligament produces that unnatural, shelf-like result you have seen on people who have clearly had something done.
Ageing then compounds it from three directions at once: the orbital rim resorbs and moves backwards, the midface fat pads descend and deflate, and the skin loses collagen and becomes progressively more translucent.
The diagnosis that changes everything
Here is the single most important thing in this article.
"Dark circles" is a description, not a diagnosis. There are at least six distinct causes, they look superficially similar in a bathroom mirror, and they require completely different treatments.
1 · Structural shadowing. A genuine hollow casting a shadow. Test it by shining a light directly from the front: if the darkness largely disappears, it is shadow. This responds to volume restoration.
2 · Vascular translucency. The skin has become thin enough that the underlying orbicularis muscle and its rich venous plexus show through. The colour is bluish or purple, and it does not vanish under direct light. This needs skin thickening, not volume.
3 · Pigmentation. Genuine excess melanin, either constitutional or post-inflammatory. The colour is brown rather than blue, and stretching the skin gently does not change it. This is common in Fitzpatrick skin types III to V, which describes most of our patients in Malaysia. Filler does nothing whatsoever for this. Nothing.
4 · Skin laxity and crepiness. Fine crinkled texture that becomes obvious when you smile. This is a collagen problem.
5 · Fluid retention, malar oedema and festoons. Soft, boggy swelling that is worse in the morning, worse after salty food, worse after a poor night's sleep. This is an absolute red flag. Injecting hyaluronic acid into a region with compromised lymphatic drainage makes it dramatically and persistently worse.
6 · Fat pad prolapse. True herniation of orbital fat producing a bulge with a groove beneath it. This is a surgical problem. Filling the groove to camouflage the bulge is a compromise, and often a poor one.
Most real patients present with a combination of three or four of these. Which is why any clinic offering a fixed under-eye filler package without an examination is selling a product rather than practising medicine.
Choosing the product: rheology over branding
I am not permitted to name specific injectable brands in public-facing material under Malaysian advertising regulations, and I would argue you should not be choosing by brand anyway. What matters are the physical properties of the gel, and the periorbital region is unforgiving about all of them.
Low hydrophilicity is the priority. Hyaluronic acid binds water, which is exactly what you want in a cheek and exactly what you do not want beneath an eye. A product with high water uptake placed under thin skin with sluggish lymphatic drainage will produce a puffy, swollen look weeks after the swelling from the procedure has settled. Modern gels engineered specifically for the periorbital area are formulated to minimise this.
Low to moderate elastic modulus, high cohesivity. You need a gel soft enough to integrate smoothly and not palpate as an edge, but cohesive enough to stay where it was placed rather than spreading.
Fine, smooth particle structure. Under half-millimetre skin, texture is visible. It genuinely is that thin.
A separate category: skin quality boosters. Lightly cross-linked or non-cross-linked hyaluronic acid delivered intradermally in tiny aliquots. These are not volumisers. They improve hydration, dermal thickness and light reflectance, which is precisely what the vascular translucency group needs and precisely what a volumising filler cannot deliver.
All injectable products we use are registered with Malaysia's Medical Device Authority. If a clinic quotes you a price notably below the market, ask what they are using and where it came from. The counterfeit filler trade in this region is real and it is growing.
Technique: how we actually do it
Deep placement, on bone. Product is delivered in the supraperiosteal plane, beneath the orbicularis muscle, directly onto the maxilla. Superficial placement is what causes the bluish discolouration many patients notice afterwards.
That discolouration has a name, and it is worth understanding. It is the Tyndall effect: when a clear gel sits too superficially under translucent skin, it scatters shorter blue wavelengths of light back towards the observer more than longer red ones. The result is a blue-grey cast that can look worse than the shadow the patient came in to fix. It is a placement error, not a product defect, and it can persist for a long time.
Cannula, not needle, in most cases. A blunt-tipped cannula introduced through a single lateral entry point is significantly less likely to penetrate a vessel than a sharp needle. Given what is at stake in this region, I regard this as close to non-negotiable.
Treat the foundation before the trough. This is the technical point most likely to change your result. In a large proportion of patients, the under-eye hollow is a consequence of midface deflation. Restore support at the anterior cheek and lid-cheek junction, and the tear trough shadow often improves substantially before a single drop goes near the orbital rim. Injectors who treat the hollow in isolation are chasing a symptom.
Under-correct, always. Small volumes, delivered slowly under low pressure. This region continues to integrate product over several weeks, and hyaluronic acid placed here has been shown on imaging to persist far longer than the marketed duration, in some cases for years. There is no prize for finishing in one session. We would rather review you at four weeks and add a little than spend six months dissolving an overcorrection.
Staged sessions. Two appointments, spaced several weeks apart, produce better and safer outcomes than one ambitious one.
Combining injectables with energy-based devices
Filler solves a structural problem. It does not thicken skin, it does not build collagen, and it does not improve pigment or texture. For patients whose darkness is driven by translucency, crepiness or laxity, an injectable alone will disappoint, and adding more of it will disappoint further.
This is why our periorbital protocols are usually combination protocols.
Er:YAG in non-ablative SMOOTH mode. The Fotona SMOOTH modality uses a 2940nm Er:YAG laser delivered as a long pulse train that heats the dermis without ablating the surface. In the periorbital application, the aim is controlled thermal stimulation of collagen and elastin remodelling around the eye, improving skin firmness and fine crinkling with essentially no downtime. It suits patients with crepey texture, fine periorbital lines and mild laxity, and patients whose main complaint is that their eye area looks tired rather than hollow.
Micro-focused ultrasound in booster configuration. The Ultraformer MPT platform delivers macro-focused ultrasound energy to defined depths. In booster mode, using superficial cartridges appropriate to the delicate periorbital tissue, energy is deposited in the upper dermis to stimulate neocollagenesis and improve skin quality and reflectance. It suits patients needing dermal thickening and mild lifting at the lid-cheek junction, especially where thin skin is allowing vascular colour to show through.
A safety note that matters: focused ultrasound is never delivered inside the bony orbital rim. The globe is not a structure to be adventurous around. Treatment stays on the orbital rim and below, and appropriate eye shielding is used.
How we sequence it. Energy first, injectable second, separated by an appropriate interval. There are two reasons. Clinically, improving skin quality first often reduces how much volume is actually required, and occasionally removes the need for it. Practically, delivering thermal or ultrasound energy over recently placed hyaluronic acid is best avoided.
The logic across the whole protocol is simple: treat shadow with structure, treat translucency with skin quality, and treat pigment as pigment. Most disappointing under-eye results come from using one tool against all three problems.
The risks, stated plainly
I would rather you read this section than the previous one.
Vascular occlusion and visual loss. This is the complication that matters. The periorbital region contains the angular artery, the infraorbital artery and branches of the ophthalmic circulation. If filler is injected into an artery under pressure, it can travel retrogradely into the ophthalmic artery and occlude the retinal circulation. The result is sudden, painful, and in most reported cases permanent, vision loss.
It is rare. It is not theoretical. The periorbital region, along with the glabella and nose, is among the highest-risk zones in the face for filler-associated blindness. This risk is the entire reason we use cannulas, inject in small volumes at low pressure, place product deep on bone, and insist that whoever holds the syringe understands the vascular anatomy in three dimensions.
Ask any clinic you are considering two questions: do you keep hyaluronidase on the premises, and what is your written protocol if a vascular event occurs. A competent clinic will answer immediately. The answer to that question tells you more than any before-and-after gallery.
Malar oedema and persistent puffiness. The most common cause of an unhappy tear trough patient. Where lymphatic drainage is already marginal, hydrophilic product placed in this region can produce swelling that persists for months or years. Patients with pre-existing morning puffiness, malar mounds or festoons are at particular risk, and in many of them we decline to inject at all.
Tyndall effect. The blue-grey discolouration described above, caused by superficial placement. Correctable with hyaluronidase, but far better avoided.
Prolonged persistence and migration. Imaging studies have repeatedly found hyaluronic acid still present in the tear trough long after patients were told it would be gone. Product placed in this low-mobility region can also migrate over time, producing gradual puffiness that patients often mistake for ageing and treat with more filler. This is how the characteristic overfilled under-eye develops: slowly, and with good intentions at every individual step.
Other recognised risks. Bruising, which is common here given the vascularity and thin skin. Contour irregularity and palpable lumps. Infection. Delayed inflammatory nodules, occasionally triggered months later by illness or vaccination. Asymmetry.
When we say no. We decline treatment where there are significant festoons or malar oedema, true fat prolapse better addressed surgically, active infection or inflammatory skin disease in the area, unrealistic expectations, or where the primary problem is pigmentary and the patient wants filler regardless. Turning patients away is not lost business. It is the reason the rest of our patients get good results.
Frequently asked questions
It addresses darkness caused by shadowing from a structural hollow. It does not treat melanin pigmentation, and it treats vascular translucency only partially. This is why assessment determines the plan.
Most patients see results maintained for around nine to eighteen months, though imaging evidence shows product can persist substantially longer in this particular region. We generally advise reviewing rather than automatically re-treating.
Topical anaesthetic is applied, and most products contain lidocaine. Cannula technique is generally more comfortable than needle. Most patients describe pressure rather than pain.
Bruising is common and may last five to ten days. Swelling settles over one to two weeks. We advise scheduling at least two weeks before any significant event.
Yes. Hyaluronic acid fillers can be dissolved with hyaluronidase. This is one of the reasons we use only hyaluronic acid based products in this region, and never permanent or semi-permanent fillers.
Neither age determines suitability. Anatomy does. We treat patients in their twenties with genetically inherited hollows and patients in their sixties, and we decline patients in both groups.
Come and find out what you are actually treating
If you have read this far, you know more about the under-eye region than most people who have already had it injected.
The most valuable thing we can offer you is not a syringe. It is fifteen minutes of proper assessment: examining your skin thickness, testing whether your darkness is shadow, vascular or pigmentary, evaluating your lymphatic drainage and midface support, and telling you honestly which of those six causes are contributing to what you see in the mirror.
Some patients leave with a filler plan. Some leave with an energy-based plan. Some leave with a pigment protocol and a strong recommendation about their sleep. And some leave having been told, with reasons, that the treatment they came in asking for would have made things worse.
All four of those are good consultations.
This article is general educational information about aesthetic medical procedures. It is not medical advice, a diagnosis, or an offer of treatment, and it does not replace individual assessment by a qualified medical practitioner. All aesthetic procedures carry risks, which are described above. Suitability, technique and outcomes vary between individuals, and no result can be guaranteed. Injectable and energy-based treatments should be performed only by appropriately trained and registered medical practitioners.